SCHEMBL18014684

SCHEMBL18014684

Cc1cc(F)c2c(ccn2C)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.38
APOBEC3A P31941 1/20 0.38
APOBEC3G Q9HC16 1/20 0.38
PTGER3 P43115 1/20 0.37
CDK4 P11802 5/20 0.35
CCND1 P24385 5/20 0.35
CCNE2 O96020 4/20 0.35
CCNE1 P24864 4/20 0.35
CDK2 P24941 4/20 0.35
PRKCI P41743 1/20 0.34
CYP2A6 P11509 4/20 0.32
CYP1A2 P05177 2/20 0.32
HTR2A P28223 1/20 0.32
HTR2C P28335 1/20 0.32
PIK3CB P42338 1/20 0.32
HTR1D P28221 1/20 0.31
HTR1B P28222 1/20 0.31
PRKACA P17612 1/20 0.31
PRKACG P22612 1/20 0.31
PRKACB P22694 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16982968 0.78 CYP2A6 (0.40) KDM4EAPOBEC3AAPOBEC3GCDK4CCND1
SCHEMBL18876125 0.77 KCNH2 (0.40) PTGER3CDK4CCND1CCNE2CCNE1
SCHEMBL17452813 0.77 CYP1A2 (0.39) PTGER3CDK4CCND1CCNE2CCNE1
SCHEMBL16629554 0.77 CDK4 (0.36) PTGER3CDK4CCND1CCNE2CCNE1
SCHEMBL18876110 0.77 PTGER3 (0.34) PTGER3CDK4CCND1CCNE2CCNE1
SCHEMBL18876128 0.77 PTGER3 (0.34) PTGER3CDK4CCND1CCNE2CCNE1
SCHEMBL18876149 0.76 CDK4 (0.36) KDM4EAPOBEC3AAPOBEC3GPTGER3CDK4
SCHEMBL26800825 0.76 BRD9 (0.39) KDM4EAPOBEC3AAPOBEC3GCDK4CCND1
SCHEMBL12536131 0.75 CDK4 (0.39) KDM4EAPOBEC3AAPOBEC3GCDK4CCND1
SCHEMBL18876176 0.75 KDM4E (0.38) KDM4EAPOBEC3AAPOBEC3GCDK4CCND1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11193065-B2 Liquid crystal composition, method of producing the same, and retardation film constituted from the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2021-12-07 US disclosed
US-20200165519-A1 POLYMERIZABLE LIQUID CRYSTAL COMPOSITION AND RETARDATION PLATE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2020-05-28 US disclosed
US-20190276744-A1 LIQUID CRYSTAL COMPOSITION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2019-09-12 US disclosed
US-10336938-B2 Liquid crystal composition SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2019-07-02 US disclosed
US-20170306234-A1 LIQUID CRYSTAL COMPOSITION, METHOD OF PRODUCING THE SAME, AND RETARDATION FILM CONSTITUTED FROM THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-10-26 US disclosed
US-20170306234-A1 LIQUID CRYSTAL COMPOSITION, METHOD OF PRODUCING THE SAME, AND RETARDATION FILM CONSTITUTED FROM THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-10-26 US disclosed
US-20170283700-A1 LIQUID CRYSTAL COMPOSITION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-10-05 US disclosed
US-20170283700-A1 LIQUID CRYSTAL COMPOSITION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-10-05 US disclosed
US-20170145312-A1 LIQUID CRYSTAL COMPOSITION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-05-25 US disclosed
US-20170145312-A1 LIQUID CRYSTAL COMPOSITION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-05-25 US disclosed
US-20160229847-A1 NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS PFIZER (US) 2016-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160229847-A1 NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS BACE1, BACE2, PSEN2 KDM4E 2364/4885APOBEC3A 3375/4885APOBEC3G 2644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.